|
|
| |
While there are more treatments for psoriasis and psoriatic arthritis available today than ever before, many people continue to need additional options.
The good news is that there are literally dozens of potentially effective treatments in development by the pharmaceutical and biotech industries, specifically for psoriasis and psoriatic arthritis.
What follows is a list of these drugs.
Many of these will never make it to market, but many of them WILL. Perhaps one of these will help you or one of your loved ones someday.
We have not included the dozens of treatments being studied for rheumatoid arthritis, even though some of them will almost certainly end up helping psoriasis and/or psoriatic arthritis patients as well. Similarly, there are treatments being investigated for other inflammatory diseases—some of these treatments may help us as well. This list focuses on those potential treatments being studied specifically for psoriasis and psoriatic arthritis.
If you think you may want to participate in a clinical trial, visit the U.S. Government's clinical trials website for psoriasis and psoriatic arthritis.
Be hopeful!
Phase III
Phase Three clinical trials are advanced trials for drugs that could come to market in anywhere from a few months to a couple years, if the results for safety and efficacy pan out. These are the drugs closest to market. An estimated 70% to 90% of drugs will succeed in Phase Three trials and reach patients.
Drugs are listed as follows: The brand name, if there is one, is followed by the generic name (in parentheses) followed by the disease for which it is being investigated, followed by the name of the company (or in some cases, the university) investigating the drug.
ABT-874 for psoriasis. Abbott Laboratories (See also this)
BG-12 (oral fumarate) for moderate to severe psoriasis. Biogen Idec
Golimumab (CNTO 148) for psoriatic arthritis. Centocor (Golimumab is currently pending before European regulators for psoriatic arthritis.)
Primolux for psoriasis. Connetics
Tacrolimus Gel for psoriasis. Astellas Pharma
Ustekinumab (CNTO 1275) for psoriasis. Centocor. [Results of Phase Three trials. Now before the FDA, a decision on ustekinumab is expected by the end of 2008.]
Voclosporin (ISA247, ISATX247) for psoriasis. Isotechnika. More info here. [This is a European/Canadian Phase Three trial.]
----------------------------------------
[The list continues below. Please take a moment first to sign a letter to goverment officials....]
----------------------------------------
Phase II
Phase Two clinical trials have passed an initial screening in human subjects, and based on that limited data, appear safe. Scientists also typically have some theory at this stage for why a particular compound may help a particular disease. Phase Two studies test a drug for effectiveness. These drugs are typically 3-5 years away from market, provided the Phase Two and later Phase Three trials prove successful. About one-third of drugs that enter Phase One studies proceed successfully through both Phase One and Phase Two trials.
Amevive (alefacept) for psoriatic arthritis. Astellas Pharma
ART621 for psoriasis. Arana Therapeutics Limited (AAH) [non-US trial]
Asord (becocalcidiol, QRX-101) for moderate psoriasis. QuatRx Pharmaceuticals Co.
Bicillin L-A (Penicillin G benzathine) for psoriasis. University of Tennessee. More info here.
Bimosiamose for psoriasis. Revotar Biopharaceuticals
BMS-582949 for psoriasis. Bristol-Myers Squibb
Carbenoxolone gel for psoriasis. York Pharma
CC-10004 for severe plaque psoriasis. Celgene
CEP-701 for psoriasis. Cephalon
CF101 for psoriasis. Can-Fite BioPharma
Cimzia (certolizumab pegol, CDP870) for psoriasis (FDA approved for Crohn's disease). UCB
CP-690,550 for psoriasis and rheumatoid arthritis. Pfizer
CRx-191, CRx-197 for psoriasis. CombinatoRx
CTA018 for psoriasis. Cytochroma. (More info here, but they are looking to transfer rights to this.)
Curcuminoid C3 Complex (curcuminoids of the root of turmeric [Curcuma Longa]) for psoriasis. University of Pennsylvania. The trial did not support consuming this as an effective psoriasis treatment.
Dermylex (XP-828L) for mild to moderate psoriasis. Advitech
E6201 for psoriasis. Eisai Medical Research Inc.
Elidel (pimecrolimus/ASM981) for psoriasis. Novartis Pharmaceuticals
Fluphenazine decanoate for psoriasis. Tufts-New England Medical Center
hOKT3gamma1 (Ala-Ala) for psoriatic arthritis. NIAID
IC747 for moderate-to-severe psoriasis. Icos Corp. and Biogen Idec
IDEC-114 for psoriasis. Biogen Idec
IDEC-131 for psoriasis. Biogen Idec
Anti-IL-12/IL-23 antibodies for psoriasis. For a brief discussion of their promise, listen to our July 2006 Psoriasis Cure Now Podcast (starting at 4:15 in the podcast).
Isis 104838 for psoriasis. Isis Pharmaceuticals
JB991 for psoriasis. Biovitrum and Synphora
LR-103 for psoriasis. Bone Care International
MM-093 for psoriasis. Merrimack Pharmaceuticals
Ontak (denileukin diftitox) for severe psoriasis. Ligand Pharmaceuticals
Paxceed (paclitaxel) for severe psoriasis. Angiotech Pharmaceuticals
PH-10 for psoriasis. Provectus Pharmaceuticals
PhotoPoint MV9411 for plaque psoriasis. Miravant Medical Technologies
Pioglitazone given with acitretin for plaque psoriasis. Postgraduate Institute of Medical Education and Research, India
Psoraxine (AS210) for moderate-to-severe plaque psoriasis. Astralis Ltd.
PsorBan (CGC1072) for psoriasis. CellGate, Inc.
PTH (1-34) for psoriasis. IGI/Manhattan Pharmaceuticals
PVAC for mild-to-moderate plaque psoriasis. Corixa Corp. and Medicis Pharmaceutical Corp.
R3421 for moderate to severe psoriasis. Hoffmann-La Roche
Rambazole for moderate to severe psoriasis. Barrier Therapeutics
STA-5326 for psoriasis. Synta Pharmaceuticals.
Tacrelimus Cream for psoriasis. Fujisawa Healthcare
Tadekinig-a (Tadekinig-alpha or IL-18 BP) for psoriasis. Serono
Targretin (bexarotene) for severe psoriasis. Ligand Pharmaceuticals
Tisocalcitrate for mild-to-moderate psoriasis. Berlex
VTP-201227 for psoriasis. Vitae Pharmaceuticals
Xantryl for psoriasis. Provectus Pharmaceuticals
Phase I
Phase One clinical trials are early stage trials that examine different dosage levels in a small number of healthy human volunteers, focused on safety. These drugs are many years from market, and many will not make it to market, although roughly 70% of these drugs will proceed to Phase Two trials. Prior to Phase One testing, drugs are tested in cells in test tubes and in animals.
AMG 714 for psoriasis. Amgen [AMG 714 is a fully human monoclonal antibody that targets interleukin-15 (IL-15).]
AN2728 for psoriasis. Anacor Pharmaceuticals
Apollo topical agent for psoriasis. Apollo Life Sciences
ATL-1101 for psoriasis. Antisense Therapeutics
BCI-202 for psoriasis. Bone Care International
BCT194 for psoriasis. Novartis
BCX-4208 (DADMe-Immucillin-H) for autoimmune diseases including psoriasis. BioCryst Pharmaceuticals/Roche/Industrial Research Ltd.
CH-1504 for psoriasis. Chelsea Therapeutics
Clofarabine gel (Evoltra) for psoriasis. Bioenvision
CRA-028129 for psoriasis. Celera Genomics
Hectorol Oral (doxercalciferol) for psoriasis. Bone Care International
IC 776 for psoriasis. Icos Corp.
ILV-094 for psoriasis. Wyeth
KC706 for inflammatory conditions including psoriasis. Kemia
LGD 1550 for psoriasis. Ligand Pharmaceuticals
MEDI-545 (previously known as MDX-1103) for psoriasis. MedImmune
P38 Antagonist to reduce expression of a variety of inflammatory mediators, including tumor necrosis factor and interleukin-1 Amgen Inc.
Paclitaxel Gel for mild-to-moderate psoriasis. Angiotech Pharmaceuticals
Pralnacasan for psoriasis. Aventis Pharmaceuticals
tgAAC94 for psoriatic arthritis. Targeted Genetics Corporation
Other drugs that may be developed for psoriasis and/or psoriatic arthritis
These drugs are being considered or mentioned for psoriasis and/or psoriatic arthritis, but their U.S. approval, if ever, would be many years away.
Aminopterin for psoriasis. Syntrix Biosystems
Avandia (rosiglitazone) for psoriasis. GlaxoSmithKline [This diabetes treatment, when tested as a psoriasis treatment, failed in large Phase Three studies to beat placebo.]
CH-1504 for psoriasis and psoriatic arthritis. Chelsea Therapeutics
K252a for psoriasis. Bio3 Research/Creabilis Therapeutics/Cephalon, Inc.
MT203, a GM-CSF neutralizing monoclonal antibody for psoriasis. Micromet.
NOV-002 for psoriasis. Novelos Therapeutics
SPHD400 for psoriasis. Sinclair Pharma plc
TRX4 (ChAglyCD3) for psoriasis. TolerRx
VX-765 for psoriasis. Vertex Pharmaceuticals [As of Oct. 2005, "The Company expects to minimize its own future development investment in ... VX-765, an interleukin-1 beta converting enzyme (ICE) inhibitor for the treatment of psoriasis."
WBI-1001 for psoriasis. Welichem Biotech
Revised April 25, 2008
|
|
|
|
